Methylphenidate in Childhood Apraxia of Speech
A legfontosabb adatok
- Ki végzi
- Murdoch Childrens Research Institute
- Hol
- Ausztrália1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 18 fő vett részt
- Kezdés
- 2022. márc. 14.
- Befejezés
- 2025. okt. 27.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Methylphenidate Hydrochloride
- Placebo
- A regiszteradat frissítve
- 2026. október 13.
Ki vehet részt
- Életkor
- 6 év – 12 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Has childhood apraxia of speech
- Aged 6-12 years
- Can perform the speech tasks for the trial (able to speak single words and short sentences)
- English as a first language
- Has adequate hearing
- Has a legally acceptable representative capable of understanding the informed consent document and providing consent on their behalf
- Passes the health and medical examination including examination of heart rate and blood pressure for age and weight norms
- Can commit to the time requirements of the trial
- Lives within 250 kilometres of the study site (MCRI)
- Able to swallow a capsule
- Scores 13 or more out of 27 on either the inattention and/or hyperactivity subscales of the SNAP-IV Parent 18-Item Rating Scale, suggesting clinically significant symptoms of inattention and/or hyperactivity
Ki nem vehet részt
- Has a diagnosis of severe intellectual disability, or other significant neurodevelopmental conditions (e.g., Fragile X, Down Syndrome, etc.)
- Has epilepsy or other seizure disorders
- Is taking medication(s) for another health condition(s) that is known to interfere with MPH
- Has any contraindication to the stimulant (methylphenidate) medication, including severe anxiety, depression, severe Tourette syndrome, glaucoma, psychotic symptoms, hypertension, congenital heart disease, known past or present diagnosed substance abuse or dependence
- Is unable to commit to the time requirements of the trial (8 weeks + 2 days)
- Has a score of moderate or high risk of suicidality, assessed with the Columbia Suicidality Severity Rating Scale (C-SSRS)
- Has used psychostimulants within the past 3 months (e.g., Ritalin, Concerta, Focalin)
- Lives more than 250 kilometres from the study site
- Unable to swallow a capsule
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to describe the possible effects of methylphenidate (MPH) on speech intelligibility in children with childhood apraxia of speech (CAS) aged 6-12 years. This outcome will be compared between MPH intake and placebo intake.
A vizsgálat 2 csoportja
- Sequence A: Methylphenidate, PlaceboA vizsgált kezelés
Participants will first receive methylphenidate capsules twice daily for four weeks. Doses will be administered four hours apart. The maximum dose is determined based on the participant's weight. After a 2-day washout, participants then receive Placebo (matching methylphenidate capsules) twice daily for four weeks.
Kezelés: Methylphenidate Hydrochloride és Placebo
- Sequence B: Placebo, MethylphenidateA vizsgált kezelés
Participants will first receive Placebo capsules twice daily for four weeks. Doses will be administered four hours apart. After a 2-day washout, participants then receive methylphenidate capsules (matching Placebo capsules) twice daily for four weeks. The maximum dose is determined based on the participant's weight.
Kezelés: Methylphenidate Hydrochloride és Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase II Proof-of-concept Trial of Methylphenidate in Children With Apraxia of Speech: a Double-blind, Randomised, Placebo-controlled, Cross-over Trial
- A regiszteradat frissítve
- 2026. október 13.